Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial

Clalit Health Services

Status: Unknown

Conditions: Parkinson Disease

Study type: Observational

Funder types: Other

Identifiers

NCT01709461

RD 06 - 12

Details and patient eligibility

About

the purpose of the study is to extend the use of Rasagelin Mesylate 1mg per day by subjects who participated in the Adagio TVP 1012/501 according to form 4a for additional three years.

Enrollment: 12 estimated patients

Sex: All

Ages: 30 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• subjects who are willing to contiue this treatment.
• subjects who took part in the TVP 1012/501 clinical trail.

Exclusion criteria

• subjects who didn't take part in the TVP 1012/501 clinical trail.